Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 2/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181106 | 0.89 | WNT3A (0.48) | KMT2AWNT3ACTNNB1LOXL2CES1 | |
| SCHEMBL6182682 | 0.87 | MAP4K4 (0.47) | TGFBR1TLR7RAB9AKMT2ALOXL2 | |
| SCHEMBL6181580 | 0.87 | WNT3A (0.45) | TGFBR1TLR7RAB9AMEN1KMT2A | |
| SCHEMBL6184116 | 0.86 | TRPV1 (0.48) | TGFBR1TLR7MEN1KMT2AWNT3A | |
| SCHEMBL6179073 | 0.86 | TLR7 (0.47) | TLR7RAB9AMEN1KMT2AWNT3A | |
| SCHEMBL6180356 | 0.84 | RAB9A (0.48) | TGFBR1TLR7RAB9AMEN1KMT2A | |
| SCHEMBL6180198 | 0.84 | TGFBR1 (0.47) | TGFBR1RAB9AMEN1KMT2AWNT3A | |
| SCHEMBL6180999 | 0.83 | TLR7 (0.49) | TLR7RAB9AMEN1KMT2AWNT3A | |
| SCHEMBL6703618 | 0.83 | RAB9A (0.51) | TGFBR1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL38664275 | 0.82 | RAB9A (0.54) | TLR7RAB9AMEN1KMT2AWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355903-B1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | SMITHKLINE BEECHAM CORP (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | US | disclosed |
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1355903-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002066462-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | TGFBR1, TGFB1, TGFBR2 | TGFBR1 1/4885TLR7 2928/4885RAB9A 3471/4885 |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TLR7 4535/4885RAB9A 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.